140 related articles for article (PubMed ID: 38649732)
1. Discovery of gefitinib-1,2,3-triazole derivatives against lung cancer via inducing apoptosis and inhibiting the colony formation.
Gao E; Wang Y; Fan GL; Xu G; Wu ZY; Liu ZJ; Liu JC; Mao LF; Hou X; Li S
Sci Rep; 2024 Apr; 14(1):9223. PubMed ID: 38649732
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and In Vitro Antitumor Activity Evaluation of Gefitinib-1,2,3-Triazole Derivatives.
Liu Z; Liu J; Gao E; Mao L; Hu S; Li S
Molecules; 2024 Feb; 29(4):. PubMed ID: 38398589
[TBL] [Abstract][Full Text] [Related]
3. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
Sun C; Gao W; Liu J; Cheng H; Hao J
Respir Res; 2020 Aug; 21(1):210. PubMed ID: 32778129
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
[TBL] [Abstract][Full Text] [Related]
5. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
6. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
[TBL] [Abstract][Full Text] [Related]
7. p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer.
Rho JK; Choi YJ; Ryoo BY; Na II; Yang SH; Kim CH; Lee JC
Cancer Res; 2007 Feb; 67(3):1163-9. PubMed ID: 17283151
[TBL] [Abstract][Full Text] [Related]
8. CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.
Zhang K; Wang L; Wei A; Jia X; Liu X
Thorac Cancer; 2020 Jun; 11(6):1566-1577. PubMed ID: 32368855
[TBL] [Abstract][Full Text] [Related]
9. Novel compound ZCJ14, a gefitinib analog, exhibited prominent anti-cancer effect among several cancer cell lines.
Wang J; Yan PP; Wang HY; Zuo SJ; Zhang SQ; Cao YX; Cao L
Life Sci; 2022 Oct; 307():120875. PubMed ID: 35963298
[TBL] [Abstract][Full Text] [Related]
10. Molecular docking studies, biological evaluation and synthesis of novel 3-mercapto-1,2,4-triazole derivatives.
Ghanaat J; Khalilzadeh MA; Zareyee D
Mol Divers; 2021 Feb; 25(1):223-232. PubMed ID: 32067134
[TBL] [Abstract][Full Text] [Related]
11. Phenethyl isothiocyanate synergistically induces apoptosis with Gefitinib in non-small cell lung cancer cells via endoplasmic reticulum stress-mediated degradation of Mcl-1.
Zhang Q; Chen M; Cao L; Ren Y; Guo X; Wu X; Xu K
Mol Carcinog; 2020 Jun; 59(6):590-603. PubMed ID: 32189414
[TBL] [Abstract][Full Text] [Related]
12. Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer.
Kim B; Park YS; Sung JS; Lee JW; Lee SB; Kim YH
Cancer Med; 2021 Jan; 10(1):372-385. PubMed ID: 33314735
[TBL] [Abstract][Full Text] [Related]
13. Gefitinib encapsulation based on nano-liposomes for enhancing the curative effect of lung cancer.
Hu Y; Zhang J; Hu H; Xu S; Xu L; Chen E
Cell Cycle; 2020 Dec; 19(24):3581-3594. PubMed ID: 33300430
[TBL] [Abstract][Full Text] [Related]
14. Novel benzimidazole-triazole hybrids as apoptosis inducing agents in lung cancer: Design, synthesis,
Sridhar Goud N; Pooladanda V; Muni Chandra K; Lakshmi Soukya PS; Alvala R; Kumar P; Nagaraj C; Dawn Bharath R; Qureshi IA; Godugu C; Alvala M
Bioorg Chem; 2020 Sep; 102():104125. PubMed ID: 32738568
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
[TBL] [Abstract][Full Text] [Related]
16. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
Shen L; Li Z; Shen S; Niu X; Yu Y; Li Z; Liao M; Chen Z; Lu S
Lung Cancer; 2012 Dec; 78(3):193-200. PubMed ID: 22985911
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel hybrids of diaryl-1,2,4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase for cancer therapy.
Cai H; Huang X; Xu S; Shen H; Zhang P; Huang Y; Jiang J; Sun Y; Jiang B; Wu X; Yao H; Xu J
Eur J Med Chem; 2016 Jan; 108():89-103. PubMed ID: 26638042
[TBL] [Abstract][Full Text] [Related]
18. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.
Tracy S; Mukohara T; Hansen M; Meyerson M; Johnson BE; Jänne PA
Cancer Res; 2004 Oct; 64(20):7241-4. PubMed ID: 15492241
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and anti-proliferation activity of mogrol derivatives bearing quinoline and triazole moieties.
Song JR; Li N; Li DP
Bioorg Med Chem Lett; 2021 Jun; 42():128090. PubMed ID: 33964443
[TBL] [Abstract][Full Text] [Related]
20. PPARα agonist fenofibrate relieves acquired resistance to gefitinib in non-small cell lung cancer by promoting apoptosis via PPARα/AMPK/AKT/FoxO1 pathway.
Wang MS; Han QS; Jia ZR; Chen CS; Qiao C; Liu QQ; Zhang YM; Wang KW; Wang J; Xiao K; Ding XS
Acta Pharmacol Sin; 2022 Jan; 43(1):167-176. PubMed ID: 33772142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
